Stocktoria
Protagonist Therapeutics, Inc PTGX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-08-11
Protagonist Therapeutics, Inc financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46.0M | $434.4M | $60.0M | $26.6M | $27.4M | $28.6M | $231,000 | $30.9M | $20.1M | — |
| R&D expense | $159.3M | $138.1M | $120.2M | $126.2M | $126.0M | $74.5M | $65.0M | $59.5M | $46.2M | $25.7M |
| Operating income | -$158.1M | $252.8M | -$93.7M | -$131.4M | -$125.8M | -$64.5M | -$80.5M | -$42.3M | -$37.9M | -$32.7M |
| Interest expense | — | — | — | — | — | $598,000 | $169,000 | — | — | — |
| Income tax | $838,000 | $4.2M | $0 | $0 | $0 | $1.3M | -$691,000 | -$799,000 | $0 | $0 |
| Net income | -$130.1M | $275.2M | -$79.0M | -$127.4M | -$125.6M | -$66.2M | -$77.2M | -$38.9M | -$37.0M | -$37.2M |
| EPS (diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 | $-1.92 | — | — | — | — |
| Operating cash flow | $57.7M | $184.2M | -$70.2M | -$108.1M | -$107.9M | -$72.5M | -$41.5M | -$49.9M | $3.9M | -$30.0M |
| Free cash flow | $56.1M | $182.8M | -$70.8M | -$108.9M | -$109.0M | -$73.0M | -$42.5M | -$50.4M | $3.2M | -$30.3M |
| Cash & equivalents | $128.4M | $97.2M | $186.7M | $125.7M | $123.7M | $117.4M | $33.0M | $82.2M | $106.0M | $21.1M |
| Total assets | $668.2M | $744.7M | $358.0M | $247.9M | $347.7M | $324.5M | $154.9M | $139.5M | $163.7M | $94.0M |
| Total liabilities | $53.5M | $69.4M | $21.3M | $32.3M | $47.7M | $44.9M | $75.0M | $27.0M | $43.1M | $6.4M |
| Shareholders' equity | $614.7M | $675.3M | $336.7M | $215.6M | $300.0M | $279.6M | $80.0M | $112.5M | $120.6M | $87.6M |
Growth · year-over-year · Revenue CAGR 10.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -89.4% | +624.1% | +125.7% | -2.8% | -4.4% | +12293.1% | -99.3% | +54.1% | — | — |
| Net income growth | -147.3% | — | — | — | — | — | — | — | — | — |
| EPS growth | -148.5% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | -69.3% | — | — | — | — | — | — | -1673.1% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.